Philippines Business News API

{
    "totalArticles": 276816,
    "articles": [
        {
            "id": "a1dff2bfb3a080981375529562d01b90",
            "title": "BRUIN Final Analysis: Pirtobrutinib Durable in Post-Covalent BTK CLL/SLL",
            "description": "Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.",
            "content": "The noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) elicited objective response rate (ORR) of 81.6% (95% CI, 76.5%–85.9%) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously trea... [6589 chars]",
            "url": "https://www.targetedonc.com/view/bruin-final-analysis-pirtobrutinib-durable-in-post-covalent-btk-cll-sll",
            "image": "https://cdn.sanity.io/images/0vv8moc6/targetedonc/d540317758eb2817b7435dd672370798e1119298-1200x630.png",
            "publishedAt": "2025-12-07T23:25:44Z",
            "lang": "en",
            "source": {
                "id": "5e38c926c12b41af0a0d41b6f36f5328",
                "name": "Targeted Oncology",
                "url": "https://www.targetedonc.com"
            }
        },
        {
            "id": "185b47731a1e764549ec700c44c54cd0",
            "title": "Government promises 50,000 new apprenticeships in employment push",
            "description": "Funding will be used to help employ young people in sectors including AI, hospitality and engineering.",
            "content": "Government promises 50,000 new apprenticeships in youth employment push\n17 minutes ago\nKathryn Armstrong\nThe government says some 50,000 young people are expected to benefit from a programme to expand apprenticeships as it looks to tackle youth unemp... [2766 chars]",
            "url": "https://www.bbc.com/news/articles/cvgkpzpy1zno",
            "image": "https://ichef.bbci.co.uk/news/1024/branded_news/8cac/live/29cbc3d0-d3b0-11f0-8259-1ffcd3245148.jpg",
            "publishedAt": "2025-12-07T22:30:07Z",
            "lang": "en",
            "source": {
                "id": "f331a5ed3965fb59761dfcecfc7e7a34",
                "name": "BBC",
                "url": "https://www.bbc.com"
            }
        },
        {
            "id": "acd34ea863d18204b5f4d3b5321879ed",
            "title": "INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9-Mutated Myelofibrosis",
            "description": "INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations",
            "content": "Treatment with INCA033989 as monotherapy or in combination with ruxolitinib (Jakafi) was well tolerated and led to spleen and anemia responses in patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior JAK inhibitor ... [7375 chars]",
            "url": "https://www.onclive.com/view/inca033989-with-without-ruxolitinib-is-safe-drives-spleen-and-anemia-responses-in-calr-exon-9-mutated-myelofibrosis",
            "image": "https://cdn.sanity.io/images/0vv8moc6/onclive/dea332f1a51a9992702953fa69d228365973d8ab-1280x720.jpg",
            "publishedAt": "2025-12-07T21:31:44Z",
            "lang": "en",
            "source": {
                "id": "0da2d0b1fc86b8b05e122c750c98bd32",
                "name": "OncLive",
                "url": "https://www.onclive.com"
            }
        }
    ]
}